Moreover, FXR agonists prevent the development of atherosclerosis [11] and kidney diseases [41], and they are valuable for the treatment of diabetes, hyperlipidemia, and obesity [42, 43]. The gene discussed is NR1H4; the disease is hyperlipidemia.